Analysis of Acinetobacter baumannii hospital infections in patients treated at the intensive care unit of the University Hospital, Wroclaw, Poland: a 6-year, single-center, retrospective study

Figures & data

Figure 1 Percentage of Acinetobacter baumannii infections (HAIs – Acinetobacter) among the total number of HAIs.

Abbreviation: HAIs, health care-associated infections.

Table 1 Etiological analysis of health care-associated infections and the percentage of Acinetobacter baumannii infections among gram-negative bacterial infections

	Year						p-value
	2011	2012	2013	2014	2015	2016
G(-), n (%)	79 (62.2)	82 (71.3)	57 (71.25)	68 (83.9)	68 (79.1)	76 (76)	0.0266
Acinetobacter	21 (26.6)	20 (24.4)	35 (61.4)	33 (48.5)	33 (48.5)	41 (54)	0.0005
baumannii, n (%)							0.0000^*
G(+), n (%)	39 (30.7)	31 (27)	10 (12.5)	9 (11.1)	13 (15.1)	19 (19.0)	0.0246
Fungi, n (%)	9 (7.1)	2 (1.75)	13 (16.25)	4 (4.9)	5 (5.8)	5 (5.0)	0.7107

Notes: Data are presented as number and percentage value. p-value was calculated for the years 2011 vs. 2016. *p-value for the years 2011 vs. 2013.

Table 2 Incidence of Acinetobacter baumannii HAIs per 1000 patient-days

	Year							p-value
	2011	2012	2013	2014	2015	2016	Sum or mean
No. of HAIs	21	20	35	33	33	41	183
No. of patient-days	6162	5327	4445	4234	4143	4251	28,562
No. of HAIs/1000	3.39	3.75	7.87	7.79	7.96	9.64	6.4	0.00000
patient-days								0.0017^*

Notes: p was calculated for the correlation of data 2011 vs. 2016. *p-value for 2011 vs. 2013.

Abbreviation: HAIs, health care-associated infections.

Figure 2 Analysis of the share of Acinetobacter baumannii strain in hospital infections.

Note: The number of A. baumannii infections among the total number of VAP, UTI, and CLA-BSI.
Abbreviations: CLA-BSI, central line associated bloodstream infection; UTI, urinary tract infection; VAP, ventilator associated pneumonia.

Table 3 Percentage of the susceptibility of Acinetobacter baumannii strain to selected antibiotics

Strains/antibiotics	Year						p-value
	2011	2012	2013	2014	2015	2016
No. of strains	21	20	35	33	33	41
Colistin (n/%)	21/100	20/100	35/100	33/100	33/100	41/100
Amikacin	4/19	3/15	2/6	1/3	3/9	5/12	0.3563
Gentamicin	5/24	3/15	2/6	0/0	4/12	5/12	0.1352
Imipenem	9/43	3/15	2/6	0/0	1/3	3/7	0.0016
Meropenem	9/43	2/10	2/6	0/0	1/3	3/7	0.0016
Ciprofloksacin	1/5	1/5	0/0	0/0	0/0	2/5	0.737
Trimetoprim/sulfametoksazol	1/5	1/5	0/0	1/3	0/0	3/7	0.5829

Notes: Data are presented as the number of susceptible strains and % of susceptibility. p-value was calculated for the correlation of data 2011 vs. 2016.